Charity number: 1123760

Company number: 6078396

(England and Wales)

British Society for Histocompatibility and Immunogenetics

Report of the Trustees and Unaudited Financial Statements

For the year ended 31 December 2017

British Society for Histocompatibility and Immunogenetics
Contents Page
For the year ended 31 December 2017

Report of the Trustees	1 to 3
Independent Examiner's Report to the Trustees	4
Statement of Financial Activities	5
Statement of Financial Position	6
Notes to the Financial Statements	7 to 11
Detailed Statement of Financial Activities	12 to 13

British Society for Histocompatibility and Immunogenetics
Report of the Trustees
For the year ended 31 December 2017

The Trustees, who are also directors for the purposes of company law, have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2017. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2015).

OBJECTIVES AND ACTIVITIES

The objects of the Society, as stated in its Memorandum of Association, are;

To promote and protect health for the public benefit in particular by:

(a) developing and maintaining good practice in Histocompatibility and Immunogenetics by ensuring the highest professional standards of competence;

(b) encouraging the advancement of scientific research and knowledge and of its application in all aspects of Histocompatibility and Immunogenetics and disseminating the useful results thereof.

The main activities of the society that contribute to the achievement of the objectives are;

Annual Conference

The BSHI Annual Conference was held at Woodland Grange, Leamington Spa. The meeting provided an educational programme of lectures and seminars. Sessions were run allowing BSHI Members to present short papers and posters of their current research to a worldwide audience of experts.

Two awards sessions were held. The first for best abstract submitted and a session dedicated to presentations from young scientists within the society.

Objectives and aims

The trustees have considered the Charity Commission's guidance on public benefit, including the guidance 'public benefit: running a charity (PB2)'.

ACHIEVEMENTS AND PERFORMANCE

Diploma and other training courses

A successful series of one and two day training courses were held to support Trainee Clinical Scientists, Biomedical Scientists and those undertaking higher qualifications. Graduating diplomats received their awards at the Annual Conference. BSHI ran a higher training meeting for members considering taking the FRC Path examinations. BSHI also administers a CPD scheme for the membership.

Special Interest Groups

The three special interest groups were all busy this year providing educational workshops and forums for discussion between the different laboratories. The 3 active SIGs are the Antibody SIG, the Next Generation Sequencing SIG and the Haematopoietic Stem Cell SIG.

Bursaries and Grants

BSHI supplied bursaries to its members to attend scientific and educational meetings. These included the European Federation of Immunogenetics and British Society for Histocompatibility and Immunogenetics meetings. The society also awarded the Julia Bodmer Travel Award, which allows a junior member of the society the opportunity to visit another laboratory to bring back some research ideas or new technology to their own laboratory. The recipient of the award presents their findings at the BSHI annual conference.

Representation to other professional bodies

The BSHI has nominated representatives to a number of other professional organisations and these representatives link to the BSHI Committee through the Professional Advisory Group. Elected members of BPAG are responsible for co-ordinating BSHI input to official working groups and documents. BSHI is represented at the Association of Clinical Scientists, Clinical Pathology Accreditation UK Ltd, the Federation of Healthcare Science, the National External Quality Assurance Advisory Panel for Immunology, and the Royal College of Pathologists and ODT advisor groups. Establishment and maintenance of appropriate standards within H&I is addressed through the BPAG. BPAG will interact with other professional organisations e.g. European Federation for Immunogenetics, British Transplantation Society as required and set up Standards Working Groups to address specific topics.

Online Scientific Journals

BSHI continues to supply access to scientific literature that members do not readily have access to.

Publications

BSHI publishes a quarterly newsletter which is sent to all of the memberships. This contains reports from meetings, CPD journal based learning exercises and updates on developments within the society.

FINANCIAL REVIEW

Reserves

The overall reserves of the charity have decreased slightly to £149,800 but still leaving the charity in a strong position to continue to pursue its objectives for the foreseeable future.

REFERENCE AND ADMINISTRATIVE INFORMATION

Name of Charity	British Society for Histocompatibility and Immunogenetics
Charity registration number	1123760
Company registration number	6078396
Principal address	C/O Executive Business Support Ltd
	City Wharf Davidson Road
	Lichfield
	Staffs
	WS14 9DZ

Trustees

The trustees and officers serving during the year and since the year end were as follows:

Brendan Clark
Deborah Pritchard
Deborah Sage
Elizabeth Wroe
John Smith
Katy Derbyshire
Kay Poulton
Olivia Shaw
Tom Browne
Anna Barker
Sarah Peacock – Appointed October 2017
Andrea Harmer – Appointed October 2017
Paul Dunn – Appointed October 2017

Secretary Deborah Pritchard


Independent examiner

Marie Hartwell
VESEY Accounting Services Ltd
12a Birmingham Road
Sutton Coldfield
West Midlands
B72 1QG

Bankers

Barclays Bank Plc
Witham Business Centre
59 Newland Street
Witham
Essex
CM8 2AJ

Approved by the Board of Trustees and signed on its behalf by

John Smith  19 September 2018

British Society for Histocompatibility and Immunogenetics
Independent Examiners Report to the Trustees
For the year ended 31 December 2017

I report to the trustees on my examination of the accounts of the charitable company for the year ended 31 December 2017.

Responsibilities and basis of report

As the charity Trustees, who are also directors for the purposes of company law, are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiners qualified statement

I confirm that no other matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.



Marie Hartwell
VESEY Accounting Services Ltd
12a Birmingham Road
Sutton Coldfield
West Midlands
B72 1QG

19 September 2018

British Society for Histocompatibility and Immunogenetics
Statement of Financial Activities (including Income and Expenditure Account)
For the year ended 31 December 2017

	Notes	Unrestricted funds	2016
		£	£
Income and endowments from:			
Charitable activities	2	65,836	83,336
Investments	3	431	262
Total		**66,267**	**83,598**
Expenditure on:			
Charitable activities	4/5	(70,733)	(74,551)
Total		**(70,733)**	**(74,551)**
Net income/expenditure		**(4,466)**	**9,047**
Reconciliation of funds			
Total funds brought forward		154,266	145,219
Total funds carried forward		**149,800**	**154,266**

Registered Number : 6078396

British Society for Histocompatibility and Immunogenetics
Statement of Financial Position
As at 31 December 2017

	Notes	2017	2016
		£	£
Fixed assets			
Tangible assets	10	161	214
		161	**214**
Current assets			
Debtors	11	22,869	33,546
Cash at bank and in hand		128,593	121,585
		151,462	**155,131**
Creditors: amounts falling due within one year	12	(1,823)	(1,079)
Net current assets		**149,639**	**154,052**
Total assets less current liabilities		**149,800**	**154,266**
Net assets		**149,800**	**154,266**
The funds of the charity			
Unrestricted income funds	13	149,800	154,266
Total funds		**149,800**	**154,266**

For the year ended 31 December 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476,

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statement were approved and authorised for issue by the Board and signed on its behalf by:

.....

J Smith
Trustee

19 September 2018

1. Accounting Policies

Basis of accounting

The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)', Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006.

British Society for Histocompatibility and Immunogenetics meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Incoming resources

All incoming resources are included in the statement of financial activities when the Charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Income from investments is included in the year in which it is receivable.

Resources expended

Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure:

2. Income from charitable activities

	2017	2016
	£	£
Unrestricted funds		
Charitable activities		
Advertising	14,268	15,580
Subscriptions	22,990	24,224
Conference	5,362	16,095
International Journal of Immunogenetics	-	8,387
Qualifications	22,891	18,800
	65,511	**83,086**
Other member activities		
Other member activities	325	250
	65,836	**83,336**

3. Investment income

	2017	2016
	£	£
Unrestricted funds		
Bank interest receivable	431	262
	431	**262**

4. Costs of charitable activities by fund type

	2017	2016
	£	£
Unrestricted funds		
Charitable activities	39,507	44,515
Support costs	31,226	30,036
	70,733	**74,551**

5. Costs of charitable activities by activity type

	Activities undertaken directly	Support costs	2017	2016
	£	£	£	£
Support costs				
Charitable activities	39,507	31,226	70,733	74,551

6. Analysis of support costs

	2017	2016
	£	£
Charitable activities		
Management	12,231	5,049
Finance	3,388	1,705
Computer costs	2,115	1,893
EBS Admin charges	9,559	7,214
International Journal of Immunogenetics	-	10,080
Print, post & stationery	244	789
Subscriptions	580	580
Telephone	633	542
Governance costs	2,476	2,184
	31,226	**30,036**

7. Net income/(expenditure) for the year

This is stated after charging/(crediting):

	2017	2016
	£	£
Depreciation of owned fixed assets	53	71
Accountancy fees	1,440	1,440

9. Comparative for the Statement of Financial Activities

The comparative year values on the Statement of Financial Activities are for unrestricted funds.

10. Tangible fixed assets

Cost or valuation	Computer equipment
	£
At 01 January 2017	380
At 31 December 2017	**380**
Depreciation	
At 01 January 2017	166
Charge for year	53
At 31 December 2017	**219**
Net book values	
At 31 December 2017	**161**
At 31 December 2016	**214**

11. Debtors

	2017	2016
	£	£
Amounts due within one year:		
Trade debtors	9,290	10,670
Prepayments and accrued income	13,579	22,876
	22,869	**33,546**

12. Creditors: amounts falling due within one year

	2017	2016
	£	£
Trade creditors	1,823	1,079
	1,823	**1,079**

13. Movement in funds

Unrestricted Funds

	Balance at 01/01/2017	Incoming resources	Outgoing resources	Balance at 31/12/2017
	£	£	£	£
General	154,266	66,267	(70,733)	149,800
	154,266	**66,267**	**(70,733)**	**149,800**

Unrestricted Funds - Previous year

	Balance at 01/01/2016	Incoming resources	Outgoing resources	Balance at 31/12/2016
	£	£	£	£
General	145,219	83,598	(74,551)	154,266
	145,219	**83,598**	**(74,551)**	**154,266**

Purpose of unrestricted Funds

General

Unrestricted funds are funds that can only be used in accordance with the charitable objects and at the discretion of the trustees.

14. Analysis of net assets between funds

	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£
Unrestricted funds			
General	161	149,639	149,800
	161	**149,639**	**149,800**

Previous year

	Tangible fixed assets	Net current assets / (liabilities)	Net Assets
	£	£	£
Unrestricted funds			
General	214	154,052	154,266
	214	**154,052**	**154,266**

15. Company limited by guarantee

British Society for Histocompatibility and Immunogenetics is a company limited by guarantee and accordingly does not have a share capital.

British Society for Histocompatibility and Immunogenetics
Detailed Statement of Financial Activities
For the year ended 31 December 2017

	2017	2016
	£	£
INCOME AND ENDOWMENT		
Charitable activities		
Advertising	14,268	15,580
Subscriptions	22,990	24,224
Conference	5,362	16,095
International Journal of Immunogenetics	-	8,387
Qualifications	22,891	18,800
Other member activities	325	250
	65,836	**83,336**
Investments		
Bank interest receivable	431	262
	431	**262**
Total incoming resources	**66,267**	**83,598**
EXPENDITURE		
Charitable activities		
Cost of direct charitable activity	(39,507)	(44,515)
	(39,507)	**(44,515)**
SUPPORT COSTS		
Management		
Management	(12,231)	(5,049)
	(12,231)	**(5,049)**
Finance		
Finance	(3,388)	(1,705)
	(3,388)	**(1,705)**
Computer costs		
Computer costs	(2,115)	(1,893)
	(2,115)	**(1,893)**
EBS Admin charges		
EBS Admin charges	(9,559)	(7,214)
	(9,559)	**(7,214)**
International Journal of Immunogenetics		
International Journal of Immunogenetics	-	(10,080)
	-	**(10,080)**
Print, post & stationery		
Print, post & stationery	(244)	(789)
	(244)	**(789)**
Subscriptions		
Subscriptions	(580)	(580)
	(580)	**(580)**

This page does not form part of the statutory financial statements

Telephone		
Telephone	(633)	(542)
	(633)	**(542)**
Governance costs		
Governance costs	(2,476)	(2,184)
	(2,476)	**(2,184)**
Total resources expended	**(70,733)**	**(74,551)**
Net Expenditure	**(4,466)**	**9,047**